


# MODERN IMPLANT DENTISTRY

EDITED BY

Bart W. Silverman, DMD

Richard J. Miron, DDS, MSc, PhD



MODERN IMPLANT DENTISTRY





One book, one tree: In support of reforestation worldwide and to address the climate crisis, for every book sold Quintessence Publishing will plant a tree (<https://onetreepanted.org/>).

#### Library of Congress Cataloging-in-Publication Data

Names: Silverman, Bart, editor. | Miron, Richard J. (Richard John), 1983- editor.

Title: Modern implant dentistry / edited by Bart Silverman and Richard J. Miron.

Description: Batavia, IL : Quintessence Publishing Co, Inc, [2023] | Includes bibliographical references and index. | Summary: "This book is a comprehensive guide to implant dentistry and covers everything from bone metabolism to bone grafting materials, media documentation, diagnosis and treatment planning, guided surgery, immediate implant placement, sinus augmentation, single-tooth and full-arch treatment, prosthetic considerations, soft tissue augmentation, esthetics, ridge augmentation, and many other topics relevant to implant dentistry"-- Provided by publisher.

Identifiers: LCCN 2023002501 | ISBN 9781647241605 (hardcover)

Subjects: MESH: Dental Implantation--methods | Dental Implants

Classification: LCC RK667.I45 | NLM WU 640 | DDC

617.6/93--dc23/eng/20230331

LC record available at <https://lcn.loc.gov/2023002501>

A CIP record for this book is available from the British Library.

ISBN: 9781647241605



© 2023 Quintessence Publishing Co, Inc

Quintessence Publishing Co, Inc  
411 N Raddant Road  
Batavia, IL 60510  
[www.quintpub.com](http://www.quintpub.com)

5 4 3 2 1

All rights reserved. This book or any part thereof may not be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise, without prior written permission of the publisher.

Editor: Leah Huffman  
Assistant editor: Kristen Clark  
Design: Sue Zubek  
Production and illustrations: Angelina Schmelter

Printed in Croatia

# MODERN IMPLANT DENTISTRY

EDITED BY

**Bart W. Silverman, DMD**

Private Practice Limited to Oral and Maxillofacial Surgery  
New City, New York

**Richard J. Miron, DDS, MSc, PhD**

Department of Periodontology  
School of Dental Medicine  
University of Bern  
Bern, Switzerland

 **QUINTESSENCE PUBLISHING**

Berlin | Chicago | Tokyo  
Barcelona | London | Milan | Mexico City | Paris | Prague | Seoul | Warsaw  
*Beijing | Istanbul | Sao Paulo | Zagreb*



# CONTENTS

Preface *vii*  
Contributors *viii*

- 1 **Bone Metabolism Around Dental Implants** 1  
*Richard J. Miron and Angel Insua*
- 2 **Vitamin D Deficiency and Early Implant Failure** 13  
*Richard J. Miron*
- 3 **Regenerative Properties of Bone Grafting Materials:  
A Comparison Between Autografts, Allografts, Xenografts, and Alloplasts** 23  
*Richard J. Miron, Michael A. Pikos, and Yufeng Zhang*
- 4 **Medical Considerations for Dental Implant Placement** 43  
*Bart W. Silverman*
- 5 **Media Documentation for Implant Procedures** 54  
*Chris Epperson*
- 6 **Diagnostic Imaging for Dental Implant Treatment** 71  
*Christos Angelopoulos*
- 7 **Diagnosis and Treatment Planning for Dental Implant Placement** 89  
*John C. Minichetti and Cara L. Minichetti*
- 8 **Guided Surgery** 118  
*Daniel Domingue and Cory Glenn*
- 9 **Socket Preservation and Grafting** 131  
*Robert M. Bagoff and Steven M. Levenbrook*
- 10 **Use of Platelet-Rich Fibrin in Implant Dentistry** 140  
*Richard J. Miron and Nathan Estrin*
- 11 **A Predictable Method for Dental Implant Placement** 160  
*Bart W. Silverman*



- 12 **Immediate Implant Placement** 170  
*Dean Licenblat*
- 13 **Implant Placement in the Esthetic Zone** 184  
*Adam Foleck*
- 14 **Radiologic Considerations for Maxillary Sinus Floor Bone Augmentation** 199  
*R. Todd Erickson*
- 15 **Internal Sinus Elevation** 209  
*Bart W. Silverman*
- 16 **Maxillary Sinus Graft Augmentation via Lateral Window** 218  
*Joseph A. Leonetti, R. Todd Erickson, Joseph Geiger, and Bart W. Silverman*
- 17 **Fundamentals of All-on-X Treatment** 229  
*Chris Barrett*
- 18 **Fully Guided Full-Arch Surgery and Prosthetics** 241  
*Curry H. Leavitt*
- 19 **Prosthetic Options in Implant Dentistry** 252  
*Allen Aptekar*
- 20 **Prosthodontic Considerations for Full-Arch Restorations** 259  
*Jack Piermatti*
- 21 **Abutment Selection and Prosthetic Options for Fixed Restorations** 272  
*Shankar Iyer*
- 22 **Implant Overdentures** 291  
*Justin Moody*
- 23 **Achieving Optimal Soft Tissue Outcomes** 302  
*Suheil Boutros*



24	<b>Soft Tissue Grafting: Materials, Techniques, and Timing</b>	316
	<i>David H. Wong</i>	
25	<b>Partial Extraction Therapy: Single-Tooth and Full-Arch Applications</b>	327
	<i>Mark Bishara</i>	
26	<b>Peri-implantitis</b>	338
	<i>Ramón Pons and Alberto Monje</i>	
27	<b>Enhancing Peri-implant Emergence Profile and Soft Tissue Contours with GBR</b>	353
	<i>Bach Le</i>	
28	<b>Suturing Techniques and Materials for Dental Implant Surgery</b>	366
	<i>Steven J. Vorholt</i>	
29	<b>Guided Bone Regeneration: Principles and Practice</b>	386
	<i>Matthew J. Fien, Israel Puterman, Juan Mesquida, Ignacio Ginebreda, and Guillermo Bauza</i>	
30	<b>Vertical Ridge Augmentation</b>	432
	<i>Hussein S. Basma</i>	
31	<b>Dental Implant Marketing</b>	444
	<i>Marcus Hines</i>	
	<b>Index</b>	453

# PREFACE



The use of dental implants has become so widespread over the past few decades that scores of textbooks have been dedicated to this topic. As little as 50 years ago, the practice of dentistry did not include the modern implants, bone grafts, barrier membranes, or growth factors currently available in today's market. It wasn't until the late 1970s that Brånemark and his colleagues presented the two-stage threaded titanium implant procedure that we know today, following a decade of testing in various animal and human models. While the original Brånemark implant was a cylindrical fixture, over the years the shape has shifted to tapered, and many new implant types, body designs, and surface morphologies have been adopted. Entire companies have been formed with the goal of delivering faster, more predictable results to our patients. Today, the field has been trending, as rapidly as ever, into the world of digital implant dentistry. This book highlights all these groundbreaking discoveries, many of which are credited to the book's contributors—some of the most talented clinicians working in the profession today.

Over 50 authors from around the world have contributed to this textbook, all of them with different backgrounds and expertise in various subspecialties of implant dentistry. Chapters 1 to 4 focus on the biologic background for dental implants as well as medical considerations required prior to placing them, and chapters 5 and 6 are dedicated to documentation, including photography and CBCT imaging. Chapters 7 and 8 focus on treatment planning and digital workflow, and chapters 9 to 18 cover many surgical concepts, from single-tooth extraction to

guided All-on-X treatment. Chapters 19 to 22 focus on the prosthetic options available to us in implant dentistry, while chapters 23 to 31 hit upon additional topics related to the field. These include soft tissue management, treatment of peri-implant disease, the socket shield technique, and marketing of dental implant therapy.

Preparing this textbook has been a massive undertaking. The editors wanted to bring you THE book on implant dentistry so every clinician, whether a beginner or a seasoned pro, can find what they need to practice implant dentistry well and continue to improve their skills and patient outcomes. To accomplish this goal, the book was written using only evidence-based approaches performed on a daily basis by experienced clinicians. As such, the techniques and advice given are based on real-world experiences in the clinic. As an added learning tool, over 60 surgical and clinical videos are included within the book (linked via QR codes) to SHOW you what these procedures and techniques and products look like in real life, not in photographs taken in ideal conditions.

We are very proud to present this book to you, and we hope to keep it updated over time as new developments, products, techniques, and research become available. The goal will always be to provide new and experienced clinicians with the most up-to-date and evidence-based textbook written in implant dentistry. As such, it is our hope that this book will benefit all implant surgeons by adding to their current knowledge base and improving their ability to make rational, evidence-based decisions in implant dentistry.





# CONTRIBUTORS

## Christos Angelopoulos, DDS

Private Practice Limited to Oral and Maxillofacial Radiology  
New York, New York

## Allen Aptekar, DMD

Private Practice  
Richmond Hill, Ontario, Canada

## Robert M. Bagoff, DMD

Private Practice  
West Orange, New Jersey

## Chris Barrett, DDS

Private Practice  
Scottsdale, Arizona

## Hussein S. Basma, DDS

Department of Periodontology  
University of Alabama at Birmingham  
Birmingham, Alabama

## Guillermo Bauza, PhD

Research Director  
InDent Research  
Palma, Islas Baleares, Spain

## Mark Bishara, DDS

Private Practice  
Whitby, Ontario, Canada

## Suheil Boutros, DDS, MS

Private Practice Limited to Periodontics  
Grand Blanc, Michigan

## Daniel Domingue, DDS

Private Practice  
Lafayette, Louisiana

## Chris Epperson, DMD

Private Practice  
Phoenix, Arizona

## R. Todd Erickson, DDS, MS

Director of Education  
Residency Director of the Comprehensive Oral Implantology Program  
Jacksonville University  
Phoenix, Arizona

## Nathan Estrin, DMD

Private Practice Limited to Periodontics  
Sarasota, Florida

## Matthew J. Fien, DDS

Private Practice Limited to Periodontics  
Fort Lauderdale, Florida

## Adam Foleck, DMD

Private Practice  
Virginia Beach, Virginia

## Joseph Geiger, DDS

Private Practice Limited to Oral and Maxillofacial Surgery  
Miami, Florida

## Ignacio Ginebreda, DDS

UCLA School of Dentistry  
Los Angeles, California

## Cory Glenn, DDS

Director of Clinical Technology  
Blue Sky Bio  
Libertyville, Illinois

## Marcus Hines, MS

Director of Full-Arch Solutions  
BioHorizons  
Clarksburg, Maryland

## Angel Insua, DDS, MS, PhD

Department of Periodontics and Oral Medicine  
University of Michigan  
Ann Arbor, Michigan

## Shankar Iyer, DDS

Private Practice Limited to Prosthodontics  
Hillside, New Jersey



**Bach Le, DDS, MD**

Private Practice Limited to Oral and Maxillofacial Surgery  
Whittier, California

**Curry H. Leavitt, DMD, MS**

Private Practice Limited to Periodontics  
Las Vegas, Nevada

**Joseph A. Leonetti, DMD**

Private Practice Limited to Oral and Maxillofacial Surgery  
Paoli, Pennsylvania

**Steven M. Levenbrook, DDS**

Private Practice  
West Orange, New Jersey

**Dean Licenblat, BDent, MSc, BSc**

Private Practice  
Sydney, Australia

**Juan Mesquida, DDS**

Private Practice  
Palma, Islas Baleares, Spain

**Cara L. Minichetti, DDS**

Private Practice  
Englewood, New Jersey

**John C. Minichetti, DMD**

Private Practice  
Englewood, New Jersey

**Richard J. Miron, DDS, BMSc, MSc, PhD, Dr med dent**

Department of Periodontology  
School of Dental Medicine  
University of Bern  
Bern, Switzerland

**Alberto Monje, DDS, MS, PhD**

Department of Periodontology  
School of Dental Medicine  
University of Michigan  
Ann Arbor, Michigan

**Justin Moody, DDS**

Founder  
Implant Pathway  
Tempe, Arizona

**Jack Piermatti, DMD**

Private Practice Limited to Prosthodontics  
Boynton Beach, Florida

**Michael A. Pikos, DDS**

Founder and CEO  
Pikos Institute  
Trinity, Florida

**Ramón Pons, DDS, MS**

Department of Periodontology  
Universidad Internacional de Catalunya  
Barcelona, Spain

**Israel Puterman, DMD, MSD**

Private Practice Limited to Periodontics  
Washington, District of Columbia

**Bart W. Silverman, DMD**

Private Practice Limited to Oral and Maxillofacial Surgery  
New City, New York

**Steven J. Vorholt, DDS**

Private Practice Limited to Implant Surgery  
Phoenix, Arizona

**David H. Wong, DDS**

Private Practice Limited to Periodontics  
Tulsa, Oklahoma

**Yufeng Zhang, MD, DDS, PhD**

Department of Dental Implantology  
School of Stomatology  
Wuhan University  
Wuhan, China



# BONE METABOLISM AROUND DENTAL IMPLANTS

RICHARD J. MIRON  
ANGEL INSUA




## SUMMARY

Despite the increasing number of studies in the field of implant dentistry investigating novel dental implant surfaces, biomaterials, and growth factors, comparatively very few have studied the biology and metabolism of bone healing and its implication in peri-implant tissue health. The aim of this chapter is to provide a thorough understanding of the biologic properties that impact bone formation and osseointegration, including the coupling mechanisms between immune cells and bone. This chapter focuses on the various bone cells in the body—osteocytes, bone lining cells (BLCs), osteoblasts, and osteoclasts—and their bone remodeling cycle. Furthermore, the importance of immune cells and their impact on biomaterial integration during bone formation and implant osseointegration is also discussed. Finally, the putative effects of cholesterol, hyperlipidemia, and vitamin D deficiency are addressed. Such factors should be monitored during patient care, and ultimately future research should focus on these avenues as well as meticulous maintenance programs to favor both early and long-term maintenance and stability of dental implants.

## OBJECTIVES

- Understand how overall patient health directly affects dental implant osseointegration
- Understand the key cells involved in bone formation, maturation, and maintenance
- Understand the direct role of immune cells on biomaterial and dental implant integration
- Understand the essential role of optimizing the immune system prior to dental implant placement
- Investigate the relationship between vitamin D deficiency and early implant failure and how to avoid such pitfalls

**B**one regeneration requires bone grafting materials that possess excellent biocompatibility and osteoinductivity without eliciting an antigenic effect. While companies that manufacture replacement biomaterials intended to mimic autogenous bone grafts often report on their osteoconductive, osteoinductive, or osteogenic potential, autogenous bone still favors the greatest bone regeneration compared to allografts, xenografts, and synthetic alternatives because it combines all three of these properties. Thus, despite the increasing number of



**FIG 1-1** The bone remodeling cycle. Osteoclasts—cells that destroy and resorb bone—are present on the bone matrix surface and liberate growth factors and cytokines to the local microenvironment. These growth factors act on mesenchymal stem cells/progenitor cells to rapidly stimulate their proliferation and differentiation toward bone-forming osteoblasts. Osteoblasts lay new bone matrix and, once embedded within the bone matrix, become osteocytes.

new bone grafting materials brought to market as substitute replacement grafts, to date there is no true replacement for autogenous bone grafts.<sup>1</sup> Autografts carry no risk of immunologic reaction or disease transmission and provide optimal conditions for the penetration of new blood vessels and migration of osteoprogenitor cells. In contrast, many bone grafting substitutes are osteoconductive but have limited osteoinductive potential.<sup>2</sup>


For bone regeneration to take place, especially with foreign-body biomaterials such as allografts and xenografts or dental implants, there is a great need to better understand the regulatory properties and integration process of these biomaterials. After all, no matter the biomaterial placed, bone formation relies on immune-related factors working at the cellular level. The aim of this chapter is therefore to provide the biologic background on the cells involved in graft consolidation and give a brief overview of fracture healing. This chapter focuses on the bone cells involved in bone formation and dental implant osseointegration, including osteocytes, BLCs, osteoblasts, and osteoclasts, and their bone remodeling cycle. The chapter also addresses the importance of immune cells and their impact on biomaterial integration, as well as the putative effects of cholesterol, hyperlipidemia, and low vitamin D levels.

## Bone Cells: Osteoclasts, Osteoblasts, and Osteocytes

There are three main cell types in bone tissue involved in the bone remodeling cycle: osteoclasts, osteoblasts, and

osteocytes<sup>3</sup> (Fig 1-1). Osteoclasts are the bone-resorbing cells that degrade bone tissues. They are derived from hematopoietic stem cells following their differentiation from monocytes in response to two key factors: receptor activator of nuclear factor kappa-B ligand (RANKL)<sup>4</sup> and macrophage colony-stimulating factor (M-CSF).<sup>5</sup> Osteoclasts can be characterized histologically based on their multinucleated morphology and expression of tartrate-resistant acid phosphatase (TRAP), cathepsin k (CatK), and the calcitonin receptor (CTR). Their formation, activity, and survival are also regulated by various hormones (such as calcitonin and estrogen) that regulate several downstream cytokines and cellular pathways.<sup>6</sup> Activated osteoclasts form distinct and unique membrane domains, including the sealing zone, the ruffled border, and the functional secretory domain, which facilitate resorption of bone or bone graft particles.<sup>7</sup> Rearrangement of their F-actin fibers from the cytoskeleton forms a ring shape consisting of a dense continuous zone of highly dynamic podosomes.<sup>8</sup> These podosomes allow for mineralized bone to be gradually resorbed, creating grooves and tunnels on the bone surface. This process is also quite important for bone remodeling because the resorbed bone liberates calcium phosphates and growth factors contained within the bone matrix that attract bone-forming osteoblasts to the local environment.<sup>9</sup>

Osteoblasts perform the opposite role of osteoclasts and are responsible for bone formation (see Fig 1-1). They are derived from cells of the mesenchymal lineage, and their formation and development are controlled locally and systemically by several growth factors, including bone



**FIG 1-2** The fracture healing process is divided into four phases: (1) hematoma formation, (2) fibrocartilage callus formation, (3) bony callus formation, and (4) bone remodeling.

morphogenetic proteins (BMPs).<sup>10,11</sup> Osteoblasts secrete a range of molecules including growth factors, cell adhesion proteins, and other extracellular matrix molecules that support new bone formation.<sup>6</sup> While osteoblasts are forming bone, they become embedded within bone tissues and transform into osteocytes.

Contrary to the short lifespan of osteoblasts and osteoclasts, osteocytes can live for decades within the bone matrix. They no longer produce new bone and instead undergo morphologic changes, losing cytoplasm organelles and acquiring a stellar shape morphology with numerous extensions that connect to other osteocytes through the canalicular network.<sup>12</sup> Osteocytes can then transmit signals through this network similar to neuron communication; this communication has a profound impact on neighboring osteoblasts, osteoclasts, and osteocytes. While it was initially believed that osteocytes served only a mechanical transduction function,<sup>13</sup> more recently their role has been deemed one of the most important within the bone tissues because they release numerous paracrine signals to their environment, thereby influencing both osteoblasts and osteoclasts.<sup>12,14,15</sup>

## Fracture Healing and Graft Consolidation

Fracture healing is an important process that involves various cell types and a variety of signaling pathways.<sup>3,16,17</sup> Unlike other tissues in the body, bone tends to regenerate and repair itself quite rapidly. Natural fracture healing is a four-stage process (Fig 1-2). The first step is hematoma formation. Following injury, a blood clot forms, creating a fibrin matrix with an abundance of infiltrating inflammatory and immune cells that take place with an activation of platelets.<sup>16,18</sup>

These cells secrete an array of growth factors that initiate the second and third phases of fracture repair.<sup>16,18</sup> At the terminal end of the first phase, osteoclast formation occurs from precursor monocytes, and these osteoclasts invade the bone surface, commencing bone resorption.<sup>16</sup>


The second phase of fracture healing is the repair phase. During this phase, a bone callus is formed. Initially, blood vessels begin to form with infiltration of mesenchymal progenitor cells; this process is responsible for creating a fibrocartilagenous tissue that matures into bone. This woven bone is gradually replaced with dense lamellar bone to form a dense bony callus in phase 3.<sup>19</sup>

The final phase is the remodeling phase, during which the callus is gradually resorbed. In this stage, the bone is replaced by native bone lacking scar tissue.<sup>20</sup> It has been shown that during this phase, resident macrophages play a predominant role in orchestrating host cells.<sup>21,22</sup> While these four phases are not described in great detail within the present chapter, it is important to note that graft consolidation is tightly regulated by secretion of growth factors and cytokines (also secreted from autogenous bone particles and blocks). This is all tightly regulated in very distinct cell-to-cell communication events that take place during bone regeneration.<sup>3</sup>

## Role of Osteocytes and Bone Lining Cells in Bone Remodeling

### Osteocytes

Osteocytes are the pivotal cells in the regulation of bone mass and structure, along with osteoblasts and osteoclasts.<sup>23</sup> Osteoblasts are derived from mesenchymal stem cells and



**FIG 1-3** Bone remodeling after excessive implant torque. (1) Excessive torque promotes bone damage, including the osteocyte network. (2) Osteoblasts and osteoclasts are recruited from the blood, from the marrow, or from BLCs to populate the bone remodeling compartment. (3) Osteoclasts remove the damaged bone. (4) BLCs clean the debris after osteoclast resorption. (5) BLCs secrete fibrillar collagen. (6) This collagen layer allows osteoblasts to attach. (7) Osteoblasts deposit osteoid to fill the compartment. (8) Osteoblasts trapped in the osteoid become osteocytes or BLCs, after which most undergo apoptosis. (Reprinted with permission from Seeman.<sup>34</sup>)

synthesize new bone matrix.<sup>24</sup> Osteoclasts are terminally differentiated multinucleated cells from the monocyte-macrophage lineage; beyond their resorbing bone function, these cells are also a source of cytokines that play an important role in bone homeostasis.<sup>25</sup> Osteocytes are terminally differentiated osteoblasts, and their primary function is to support bone structure and mechanosensation.<sup>24</sup> Osteocytes may act as regulators of bone remodeling by modulating osteoclast and osteoblast activities.<sup>25</sup> These stellate-shaped cells are located within lacunae surrounded by mineralized bone matrix and present with connections through cytoplasmic prolongations with surface BLCs but also with bone marrow.<sup>15,25</sup>

### Bone lining cells

BLCs are cells involved in bone formation much like preosteoblasts, osteoblasts, and osteocytes.<sup>26</sup> They are characterized by a flat-shaped architecture along bony surfaces<sup>25</sup> and may be considered latent osteoblasts.<sup>27</sup> In human cancellous bone, around 65% of osteoblasts undergo apoptosis, with approximately 30% differentiating into osteocytes<sup>28</sup>; the reduced remnants become BLCs and chondroid-like cells.<sup>26,28</sup> BLCs maintain their proliferative capability and often differentiate into other osteogenic cells.<sup>29,30</sup> Various studies have shown that some factors can induce their proliferation prior to bone formation,<sup>31</sup> while mature osteoblasts are unable to divide.<sup>26</sup> Osteoblasts may also undergo a quiescent stage when there is no bone resorption or remodeling,<sup>29</sup> but the function of

BLCs might be more complex than a simple latent state,<sup>32</sup> including catabolic and anabolic bone processes<sup>31</sup> and rapid bone formation under osteogenic signaling.<sup>32</sup>

In the complex process of bone remodeling,<sup>33,34</sup> external factors such as mechanical loading, irradiation, parathyroid hormone (PTH), fibroblast growth factor-2 (FGF2), sclerostin inhibition, or inflammation may lead BLCs to exit the quiescent stage and enter into an active function phase by re-forming their cuboidal appearance and their secretory capability.<sup>25,31,35</sup> The presence of BLCs observed histologically indicates a strong sign of osteogenic potential<sup>29</sup> and is often regarded as a major source of osteoblasts and proliferating preosteoblasts in the adult population.<sup>31</sup> This prominent role in new bone formation was previously highlighted<sup>28,32</sup> when rapid bone formation was observed after mechanical loading without previous bone resorption. Early peak bone formation after 3 days was only possible if BLCs underwent reactivation and required their secretory capacities.<sup>28,32</sup>

Moreover, BLCs exert a prominent function during bone resorption,<sup>36</sup> demonstrated by their ability to express key osteoclastogenesis markers including M-CSF receptor (M-CSFR), and after the modulation of bone resorption, BLCs play another important role in the early stages of bone formation by entering the resorption lacunae to remove collagen fibers and debris left by osteoclasts (Fig 1-3). Subsequent to this cleaning function, BLCs secrete a layer of fibrillar collagen, allowing osteoblasts to attach and deposit new osteoid.<sup>36</sup>

One novel replacement option that has shown promising results both before and after surgery is StellaLife's recovery kit, a homeopathic wound healing rinse (Fig 1-5). It favors better wound healing of the defect site as well as improved pain management with microbial resistance.<sup>141</sup> A split-mouth study revealed that the StellaLife VEGA Oral Care Recovery Kit performed better than many frequently utilized materials including Peridex, plasma rich in growth factors (PRGF), platelet-rich plasma (PRP), Emdogain, and PerioSciences products. The following conclusions were reported in the StellaLife test group<sup>141</sup>:

- The product achieved anesthetic pain relief.
- Healing was faster than with the control products.
- At 1 week, the sites treated with StellaLife resembled the other sites at 1 month (those treated with Peridex, PRGF, PerioSciences, PRP, or Emdogain).
- Less pain was associated with the sites treated with StellaLife.
- Fewer problems were reported for the sites treated with StellaLife.
- The pain level (rated as 5 or less the first day followed by less than 3 the consecutive days) was lower than anticipated (7 on a scale of 1 to 10).

StellaLife was initially developed to limit the need for narcotic drugs during healing and thereby battle the growing problem of narcotic dependence and addiction in the United States. In a study of 150 patients, all patients unanimously reported having fewer problems and recovering more quickly while utilizing StellaLife's VEGA system compared to other products and therefore required fewer narcotic pain medications.

## Conclusion

While implants have been highly researched over the years, it remains equally important to better understand how loading and implant bed preparation affect BLCs and osteocyte viability and signaling both at early and late time points. Furthermore, the effects of systemic levels of cholesterol, fatty acids, and vitamin D are important factors that may affect implant survival. In addition, the prominent role of immune cells (eg, OsteoMacs and MNGCs) on bone formation, bone remodeling, and implant osseointegration and maintenance must be researched further to discover how immune cells can be controlled to favor long-term stability and prevent peri-implant disease. Future research investigating these various topics is ongoing.



**FIG 1-5** StellaLife Recovery Kit used both before and after implant surgery.

## References

1. Jensen SS, Terheyden H. Bone augmentation procedures in localized defects in the alveolar ridge: Clinical results with different bone grafts and bone-substitute materials. *Int J Oral Maxillofac Implants* 2009;24(suppl):218–236.
2. Miron RJ, Zhang YF. Osteoinduction: A review of old concepts with new standards. *J Dent Res* 2012;91:736–744.
3. Gruber R, Stadlinger B, Terheyden H. Cell-to-cell communication in guided bone regeneration: Molecular and cellular mechanisms. *Clin Oral Implants Res* 2017;28:1139–1146.
4. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. *Endocr Rev* 1999;20:345–357.
5. Hofstetter W, Wetterwald A, Cecchini MC, Felix R, Fleisch H, Mueller C. Detection of transcripts for the receptor for macrophage colony-stimulating factor, c-fms, in murine osteoclasts. *Proc Natl Acad Sci U S A* 1992;89:9637–9641.
6. Civitelli R. Cell-cell communication in the osteoblast/osteocyte lineage. *Arch Biochem Biophys* 2008;473:188–192.
7. Mulari M, Vääräniemi J, Väänänen HK. Intracellular membrane trafficking in bone resorbing osteoclasts. *Microsc Res Tech* 2003;61:496–503.
8. Luxenburg C, Geblinger D, Klein E, et al. The architecture of the adhesive apparatus of cultured osteoclasts: From podosome formation to sealing zone assembly. *PLoS One* 2007;2:e179.
9. Nesbitt SA, Horton MA. Trafficking of matrix collagens through bone-resorbing osteoclasts. *Science* 1997;276:266–269.
10. Raisz LG, Kream BE. Regulation of bone formation. *N Engl J Med* 1983;309:29–35.
11. Cao X, Chen D. The BMP signaling and in vivo bone formation. *Gene* 2005;357:1–8.
12. Rochefort GY, Pallu S, Benhamou CL. Osteocyte: The unrecognized side of bone tissue. *Osteoporos Int* 2010;21:1457–1469.
13. Manolagas SC, Parfitt AM. What old means to bone. *Trends Endocrinol Metab* 2010;21:369–374.
14. Tatsumi S, Ishii K, Amizuka N, et al. Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. *Cell Metab* 2007;5:464–475.
15. Bonewald LF. The amazing osteocyte. *J Bone Miner Res* 2011;26:229–238.
16. Einhorn TA. The cell and molecular biology of fracture healing. *Clin Orthop Relat Res* 1998;(355 suppl):S7–S21.



17. Burchardt H. The biology of bone graft repair. *Clin Orthop Relat Res* 1983;(174):28–42.
18. Dimitriou R, Tsiroidis E, Giannoudis PV. Current concepts of molecular aspects of bone healing. *Injury* 2005;36:1392–1404.
19. Bolander ME. Regulation of fracture repair by growth factors. *Proc Soc Exp Biol Med* 1992;200:165–170.
20. Marsell R, Einhorn TA. The biology of fracture healing. *Injury* 2011;42:551–555.
21. Alexander KA, Chang MK, Maylin ER, et al. Osteal macrophages promote in vivo intramembranous bone healing in a mouse tibial injury model. *J Bone Miner Res* 2011;26:1517–1532.
22. Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. *Nat Rev Immunol* 2011;11:762–774.
23. Klein-Nulend J, Nijweide PJ, Burger EH. Osteocyte and bone structure. *Curr Osteoporos Rep* 2003;1:5–10.
24. Clarke B. Normal bone anatomy and physiology. *Clin J Am Soc Nephrol* 2008;3(suppl 3):S131–S139.
25. Florencio-Silva R, Sasso GR, Sasso-Cerri E, Simoes MJ, Cerri PS. Biology of bone tissue: Structure, function, and factors that influence bone cells. *Biomed Res Int* 2015;2015:421746.
26. Franz-Odenaal TA, Hall BK, Witten PE. Buried alive: How osteoblasts become osteocytes. *Dev Dyn* 2006;235:176–190.
27. Miller SC, Bowman BM, Smith JM, Jee WS. Characterization of endosteal bone-lining cells from fatty marrow bone sites in adult beagles. *Anat Rec* 1980;198:163–173.
28. Parfitt AM. Primary osteoporosis. *Lancet* 1980;1:773–774.
29. Miller SC, de Saint-Georges L, Bowman BM, Jee WS. Bone lining cells: Structure and function. *Scanning Microsc* 1989;3:953–960.
30. Bowman BM, Miller SC. The proliferation and differentiation of the bone-lining cell in estrogen-induced osteogenesis. *Bone* 1986;7:351–357.
31. Matic I, Matthews BG, Wang X, et al. Quiescent bone lining cells are a major source of osteoblasts during adulthood. *Stem Cells* 2016;34:2930–2942.
32. Chow JW, Wilson AJ, Chambers TJ, Fox SW. Mechanical loading stimulates bone formation by reactivation of bone lining cells in 13-week-old rats. *J Bone Miner Res* 1998;13:1760–1767.
33. Davies JE. Understanding peri-implant endosseous healing. *J Dent Educ* 2003;67:932–949.
34. Seeman E. Bone modeling and remodeling. *Crit Rev Eukaryot Gene Expr* 2009;19:219–233.
35. Donahue HJ, McLeod KJ, Rubin CT, et al. Cell-to-cell communication in osteoblastic networks: Cell line-dependent hormonal regulation of gap junction function. *J Bone Miner Res* 1995;10:881–889.
36. Everts V, Delaisse JM, Korper W, et al. The bone lining cell: Its role in cleaning Howship's lacunae and initiating bone formation. *J Bone Miner Res* 2002;17:77–90.
37. Miron RJ, Bosshardt DD. OsteoMacs: Key players around bone biomaterials. *Biomaterials* 2016;82:1–19.
38. Heinemann DE, Lohmann C, Siggelkow H, Alves F, Engel I, Koster G. Human osteoblast-like cells phagocytose metal particles and express the macrophage marker CD68 in vitro. *J Bone Joint Surg Br* 2000;82:283–289.
39. Ruiz C, Perez E, Vallecillo-Capilla M, Reyes-Botella C. Phagocytosis and allogeneic T cell stimulation by cultured human osteoblast-like cells. *Cell Physiol Biochem* 2003;13:309–314.
40. Chehroudi B, Ghrebi S, Murakami H, Waterfield JD, Owen G, Brunette DM. Bone formation on rough, but not polished, subcutaneously implanted Ti surfaces is preceded by macrophage accumulation. *J Biomed Mater Res A* 2010;93:724–737.
41. Thalji G, Cooper LF. Molecular assessment of osseointegration in vitro: A review of current literature. *Int J Oral Maxillofac Implants* 2014;29:e171–e199.
42. Davison NL, Gamblin AL, Layrolle P, Yuan H, de Bruijn JD, Barrere-de Groot F. Liposomal clodronate inhibition of osteoclastogenesis and osteoinduction by submicrostructured beta-tricalcium phosphate. *Biomaterials* 2014;35:5088–5097.
43. Hume DA, Loutit JF, Gordon S. The mononuclear phagocyte system of the mouse defined by immunohistochemical localization of antigen F4/80: Macrophages of bone and associated connective tissue. *J Cell Sci* 1984;66:189–194.
44. Chang MK, Raggatt LJ, Alexander KA, et al. Osteal tissue macrophages are intercalated throughout human and mouse bone lining tissues and regulate osteoblast function in vitro and in vivo. *J Immunol* 2008;181:1232–1244.
45. Favus MJ. Primer on the metabolic bone disease and disorders of mineral metabolism [in French]. *Rev Fr Endocrinol Clin Nutr Metab* 1996;37:553–554.
46. Pettit AR, Chang MK, Hume DA, Raggatt LJ. Osteal macrophages: A new twist on coupling during bone dynamics. *Bone* 2008;43:976–982.
47. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. *Nat Rev Immunol* 2008;8:958–969.
48. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: Time for reassessment. *F1000Prime Rep* 2014;6:13.
49. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. *J Immunol* 2000;164:6166–6173.
50. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. *Ann Rev Immunol* 1997;15:323–350.
51. Pesce JT, Ramalingam TR, Mentink-Kane MM, et al. Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. *PLoS Pathog* 2009;5:e1000371.
52. Novak ML, Koh TJ. Macrophage phenotypes during tissue repair. *J Leukoc Biol* 2013;93:875–881.
53. Albrektsson T, Dahlin C, Jemt T, Sennerby L, Turri A, Wennerberg A. Is marginal bone loss around oral implants the result of a provoked foreign body reaction? *Clin Implant Dent Relat Res* 2014;16:155–165.
54. Trindade R, Albrektsson T, Tengvall P, Wennerberg A. Foreign body reaction to biomaterials: On mechanisms for buildup and breakdown of osseointegration. *Clin Implant Dent Relat Res* 2016;18:192–203.
55. Trindade R, Albrektsson T, Wennerberg A. Current concepts for the biological basis of dental implants: Foreign body equilibrium and osseointegration dynamics. *Oral Maxillofac Surg Clin North Am* 2015;27:175–183.
56. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. *Front Biosci* 2007;13:453–461.
57. Tomasi C, Tassarolo F, Caola I, Wennström J, Nollo G, Berglund T. Morphogenesis of peri-implant mucosa revisited: An experimental study in humans. *Clin Oral Implants Res* 2014;25:997–1003.
58. Ujiie Y, Todescan R, Davies JE. Peri-implant crestal bone loss: A putative mechanism. *Int J Dent* 2012;2012:742439.
59. Baixe S, Tenenbaum H, Etienne O. Microbial contamination of the implant-abutment connections: Review of the literature. *Rev Stomatol Chir Maxillofac Chir Orale* 2015;117:20–25.
60. Schmitt CM, Nogueira-Filho G, Tenenbaum HC, et al. Performance of conical abutment (Morse Taper) connection implants: A systematic review. *J Biomed Mater Res A* 2014;102:552–574.
61. Berberi A, Maroun D, Kanj W, Amine EZ, Philippe A. Micromovement evaluation of original and compatible abutments at the implant-abutment interface. *J Contemp Dental Pract* 2016;17:907–913.
62. Monje A, Ravidà A, Wang HL, Helms JA, Brunski JB. Relationship between primary/mechanical and secondary/biological implant stability. *Int J Oral Maxillofac Implants* 2019;34:S7–S23.
63. Wang L, Ye T, Deng L, et al. Repair of microdamage in osteonal cortical bone adjacent to bone screw. *PLoS One* 2014;9:e89343.
64. Duyck J, Corpas L, Vermeiren S, et al. Histological, histomorphometrical, and radiological evaluation of an experimental implant design with a high insertion torque. *Clin Oral Implants Res* 2010;21:877–884.
65. O'Brien CA, Nakashima T, Takayanagi H. Osteocyte control of osteoclastogenesis. *Bone* 2013;54:258–263.
66. Kennedy OD, Herman BC, Laudier DM, Majeska RJ, Sun HB, Schaffler MB. Activation of resorption in fatigue-loaded bone involves both apoptosis and active pro-osteoclastogenic signaling by distinct osteocyte populations. *Bone* 2012;50:1115–1122.
67. Misch CE. Bone classification, training keys to implant success. *Dent Today* 1989;8:39–44.
68. Monje A, Chan HL, Galindo-Moreno P, et al. Alveolar bone architecture: A systematic review and meta-analysis. *J Periodontol* 2015;86:1231–1248.
69. Rho JY, Tsui TY, Pharr GM. Elastic properties of human cortical and trabecular lamellar bone measured by nanoindentation. *Biomaterials* 1997;18:1325–1330.

# INDEX



Page numbers followed by “t” denote tables; “f” denote figures; and “b” denote boxes.

## A

- Absorbable sutures, 367
- Abutments
- for angled implants, 278, 280
  - ball-type, 298
  - biologic considerations for, 273–274
  - biomechanical considerations for, 274
  - for cement-retained restorations, 281–282, 282f–283f, 284
  - custom UCLA/milled, 283, 284f
  - esthetic considerations for, 275, 279–280, 282, 283f
  - external hex connection, 275, 275f
  - for free-standing restorations, 278
  - functional requirements for, 279–280
  - gold, 279
  - healing, 168, 168f, 323f, 359, 384f
  - hybrid, 277, 280, 285, 286f
  - implant–abutment connection, 273, 275–276, 279
  - internal hex connection, 276, 276f
  - multiunit, 247–248, 247f–248f, 255, 255f, 277–278, 286–287, 287f, 330
  - one-piece, 276
  - for overdentures, 298, 299f
  - prosthetic material considerations, 278–279
  - retention mode and, 277–278
  - for screw-retained implants, 277, 281, 285, 285f
  - selection considerations for, 275b, 275–287
  - for splinted restorations, 278
  - stock, 281–282, 282f–283f
  - for straight implants, 278, 280
  - titanium-base, 194, 279–280, 285, 286f
  - two-piece, 276
  - UCLA, 283, 284f
  - zirconia, 194, 274, 279–280
- AtC. *See* Glycosylated hemoglobin.
- Acellular dermal connective tissue grafts, 304, 304f, 319, 324–325, 325f
- Acute asthma attack, 50
- Acute rhinosinusitis, 203f, 203–204, 219
- Additive manufacturing, 85, 261
- Adipocytes, 7
- Adipogenesis, 7
- ALARA, 86, 98
- Alcohol consumption, 344
- Allergic rhinosinusitis, 204, 204f
- Allergy testing, 49
- Allografts
- advantages of, 29, 393t
  - bone regeneration uses of, 2
  - classification of, 24f, 413
  - demineralized freeze-dried bone, 24, 29–30
  - description of, 40, 319
  - freeze-dried bone. *See* Freeze-dried bone allograft.
  - growth factors released by, 33
  - guided bone regeneration uses of, 30, 36
  - heat treatment of, 40
  - horizontal ridge augmentation uses of, 36f
  - peri-implantitis infraosseous defect treated with, 35of
  - platelet-rich fibrin with, 147f
  - properties of, 25t
  - proportional use of, 34, 34f
  - regenerative properties of, 33–34, 34t
  - sinus augmentation uses of, 34, 35f
  - socket grafting uses of, 133
  - soft tissue, 305, 319, 324–325
  - xenografts versus, 30
- All-on-Four, 230, 269f
- All-on-X treatment, 445, 446f
- algorithm for, 232f
  - Bedrossian classification, 230, 230f–231f, 233
  - cast mounting for, 236f, 236–237
  - CBCT evaluation for, 233, 233f
  - history of, 229–230
  - multifunctional appliance in, 238f, 238–239
  - panoramic radiograph after, 25of
  - photographic series for, 234f–235f, 234–236
  - restorative phase of, 238–240, 238f–240f
  - summary of, 240
  - surgical planning, 237–238
  - tilted implants in, 233f, 233–234
  - treatment planning for, 232–237, 233f–236f
  - vertical dimension of occlusion, 236f, 236–237, 239
- Alloplasts
- biphasic calcium phosphates, 32, 32f
  - classification of, 24f
  - description of, 31–32, 393t
  - osteoconductive properties of, 31
  - properties of, 25t
  - regenerative properties of, 33–34, 34t
- Alveolar bone. *See also* Bone.
- CBCT assessment of, 79–81
  - density of, 6, 79–81
  - presurgical implant assessments, 72
  - rhBMP-2 for augmentation of, 37f
- Alveolar ridge
- atrophic, narrow-diameter implants in, 298
  - defects of, 387, 395f–397f, 396, 396t, 433–434
  - preservation of, 144, 147f
  - resorption of, 306, 327, 388, 420
- Alveolar ridge augmentation
- crown lengthening with, 188f
  - illustration of, 191f
  - soft tissue augmentation in healed sites before, 306–307
- Alveolar ridge defects, 355–357
- American Society of Anesthesiologists
- Physical Status Classification System, 47t, 47–49, 90

- Amnion-chorion membranes, 424  
 Amoxicillin, 49  
 Amoxicillin/clavulanate, 220b, 227  
 Anatomy, 44, 44f–45f  
 Angled implants, 278, 280  
 Angulated screw channel, 176  
 Anterior superior alveolar nerve, 100  
 Anterior teeth  
   immediate implant placement approaches for, 176, 177f  
   maxillary anterior tooth position, 261–262, 262f  
 Anteroposterior spread, 95, 95f, 260, 298  
 Anticoagulants, 52  
 Antioxidants, 17–18  
 Antiplatelet medications, 52  
 Antiresorptive agents, 51–52  
 Antroliths, maxillary sinus, 206f, 206–207  
 Antrums of Highmore, 209  
 Aperture, 63t, 64, 64f  
 Apical abscess, 173f  
 Articaine, 402–403  
 As low as reasonably achievable. *See* ALARA.  
 ASAN. *See* Anterior superior alveolar nerve.  
 Aspirin, 52  
 Asthma, 49–50  
 Atelocollagen-derived xenografts, 40t  
 Autogenous bone grafts  
   advantages of, 393t  
   bone blocks, 27, 27f  
   bone regeneration uses of, 1–2  
   cell viability of, 29f  
   classification of, 24f  
   contraindications for, 39t  
   description of, 24, 40  
   growth factors released by, 27, 33  
   guided bone regeneration uses of, 36–37, 148, 149f  
   harvesting of, 26–28, 27f–29f, 132, 409–410, 409f–410f, 439  
   horizontal ridge augmentation uses of, 148, 149f  
   indications for, 39t  
   for internal sinus elevation, 214  
   limitations of, 24  
   osteogenicity of, 25–26  
   properties of, 25t  
   proportional use of, 34, 34f  
   regenerative properties of, 33–34, 34t  
   vertical ridge augmentation uses of, 439  
   xenografts and, 36–37  
 Autogenous gingival grafts, 302–303, 303f, 310, 315  
 Autogenous soft tissue grafts, 319, 320f  
 Autografts. *See* Autogenous bone grafts.
- B**
- B vitamins, 19  
 Ball-type abutments, 298  
 Barrier membranes, 148, 361, 380, 413–416, 435–436, 436f  
 BCPs. *See* Biphasic calcium phosphates.  
 Bedrossian classification, 230, 230f–231f, 233  
 Benign paroxysmal positional vertigo, 212–213  
 Beta-carotene, 19  
 $\beta$ -tricalcium phosphate with collagen, 145  
 Biaxial screws, 176
- BIC. *See* Bone-to-implant contact.  
 Bio-Heat tray, 153, 155f  
 Biomaterials  
   foreign body reaction to, 5–6  
   future research in, 39–40, 40t  
   immune cells around, 14  
   ion incorporation into, 40t  
   osteoinductive potential of, 25–26  
 Bio-Oss, 28, 30–31  
 Biotin, 19  
 Biphasic calcium phosphates, 32, 32f  
 Bisecting wound technique, 374, 375f  
 Bisecting-angle technique, for periapical radiography, 72  
 Bisphosphonates, 51–52, 232  
 Blade implants, 89, 90f  
 BLCs. *See* Bone lining cells.  
 Bleeding on probing, 339, 341, 341f, 349f  
 Block grafting, 387t, 441  
 Blood clot, in wound healing, 134  
 Blood thinners, 52  
 BMF. *See* Bone marrow fat.  
 Bone. *See also* Alveolar bone.  
   cells in, 2f, 2–3, 8  
   classification system for, 102  
   clinical examination of, 52  
   density of, 79–81, 102, 103t, 190–191  
   evaluation of, 101–102  
   formation of  
     bone lining cells in, 4  
     osteoblasts in, 2f, 2–3  
   implant insertion effects on, 6–7  
   metabolism of, 7–8, 50  
   morphology assessments of, in esthetic zone, 190–191, 191f–192f  
   for overdentures, 296  
   periapical radiography assessments of, 72–73  
   resorption of, 2, 2f, 4  
 Bone augmentation  
   techniques for, 387t  
   for vertical ridge augmentation, 434–436, 434f–436f  
 Bone blocks, 27, 27f  
 Bone fracture healing, 3, 3f, 51  
 Bone grafts  
   allogeneic. *See* Allografts.  
   alloplasts. *See* Alloplasts.  
   autogenous. *See* Autogenous bone grafts.  
   bone regeneration using, 1–2, 25–26  
   characteristics of, 393t  
   classification of, 23–24, 24f, 25t, 413  
   clinical applications of, 34f–38f, 34–39  
   contraindications for, 39t  
   extraction socket uses of, 34, 34f  
   future research in, 39–40  
   for guided bone regeneration, 361  
   history of, 132  
   horizontal, 190  
   indications for, 24, 39t  
   for internal sinus elevation, 214  
   osteoinductive potential of, 25–26  
   overview of, 23–24  
   periodontal regeneration of intrabony and furcation defects using, 38–39  
   platelet-rich fibrin and, 145, 149–150, 393  
   proportional use of, 34, 34f  
   sinus augmentation uses of, 34–35, 35f  
   soft tissue augmentation before use of, 307  
   synthetically fabricated, 39t  
   xenogeneic. *See* Xenografts.  
 Bone healing  
   excessive implant torque effects on, 6–7  
   medication effects on, 51–52  
 Bone lining cells, 4  
 Bone marrow, 7  
 Bone marrow fat, 7  
 Bone mass, 7  
 Bone mill, 27, 28f  
 Bone regeneration, 387. *See also* Guided bone regeneration.  
   allografts for, 2  
   autogenous bone grafts for, 1–2  
   biological components required for, 25, 25f  
   bone grafts for, 25–26  
   macrophages in, 5–6  
 Bone remodeling  
   around implants, 6  
   bone lining cells in, 4  
   cycle of, 2f  
   excessive implant torque effects on, 4f, 6  
   external factors that affect, 4  
   in fracture healing process, 3, 3f  
   osteoblasts in, 2f, 2–3, 4f, 6–7  
   osteoclasts in, 2f, 2–3, 4f  
   osteocytes in, 2–4  
 Bone shell technique, 387t  
 Bone substitutes, 133, 181  
 Bone-borne guides, 126–127, 127f  
 Bone-supported guides, 105  
 Bone-to-implant contact, 7–8, 15–16, 34, 94, 102  
 Bony callus formation, in fracture healing process, 3, 3f  
 BOP. *See* Bleeding on probing.  
 BPPV. *See* Benign paroxysmal positional vertigo.  
 Braided sutures, 367  
 Bruxism, 344  
 Buccal bone plate thickness, 187  
 Buccal flap, 138–139, 335, 335f, 410–412, 411f, 437  
 Buccal plate, 176
- C**
- CAD. *See* Computer-assisted design.  
 Calcitonin receptor, 2  
 Caldwell-Luc technique, 199, 218  
 Camera  
   aperture for, 63t, 64, 64f  
   DSLR/mirrorless. *See* DSLR/mirrorless camera.  
   ISO, 63t, 64  
   positioning of, 64, 64f–65f  
   settings for, 62–64, 63f, 63t  
   shutter speed for, 63, 63t  
   types of, 57–58, 58f, 58t  
 Cantilevers, 109  
 Cardiovascular disease, 344  
 Caries, 91, 111f  
 Carotenoids, 19  
 Castroviejo needle holder, 368, 369f

- Cathepsin k, 2
- CBCT
- accuracy of, 78
  - All-on-X treatment use of, 233–236
  - alveolar bone density assessments using, 79–81
  - alveolar ridge defects, 395f–396f
  - bone density assessments using, 79–81, 102, 190–191
  - computer-assisted planning using, 81–86, 82f–86f
  - cross-sectional imaging uses of, 79
  - diagnostic considerations for, 78–81
  - edentulous site assessments, 78, 78f–79f
  - extended-field of view, 80f
  - focused field of view, 131
  - implant placement verification using, 215f
  - implant site assessments using, 79f, 79–81
  - of mandible, 77f, 98–100, 99f
  - of maxilla, 100–101, 101f
  - of maxillary sinus, 200, 202
  - pre-implant evaluations using, 77–86, 78f–86f
  - principles of, 76
  - radiation protection measures for, 77
  - radiologic guide created using, 83–85, 84f
  - surgical guide created using, 85, 86f
- Cefuroxime, 220b
- Cement retention, 260
- Cemento-enamel junction, 193
- Cement-retained partial denture, 195
- Cement-retained restorations
- abutments for, 281–282, 282f–283f, 284
  - custom UCLA abutments for, 284f
  - description of, 277
  - screw-retained restorations versus, 280
- Central plane of the image layer, 73
- Chief complaint, 43, 47, 90
- Chlorhexidine, 8, 227, 402, 419, 424
- Cholesterol
- bone metabolism affected by, 7
  - obesity and, 7
- Chromic gut sutures, 371, 371t
- Chronic diabetes mellitus, 50
- Chronic kidney disease, 8
- Chronic rhinosinusitis, 204, 204f
- CHX. *See* Chlorhexidine.
- Cingulum, 192
- Clindamycin, 49
- Clinical examination, 52–53, 262, 267
- Closed tray technique, for impressions, 257, 257f
- Collagen membranes, 134, 135f, 153, 155f, 226f, 414–415
- Collagen plugs, 34
- Cologne Classification of Alveolar Ridge
- Defects, 396, 433f, 433–434
- Columbia retractors, 68, 69f
- Common carotid artery, 210
- Communication, 56, 56f
- Computer-assisted design, 85, 109
- Computer-assisted planning, 81–86, 82f–86f
- Concha bullosa, 201–202, 202f
- Connective tissue grafts
- acellular dermal, 304, 304f, 319, 324–325, 325f
  - description of, 172, 193, 354
  - guided bone regeneration and, 423
  - subepithelial, 302–304, 304f, 306–307, 308f, 310, 311f, 322–323, 323f, 325, 336
- Consultation, 43
- Continuous horizontal mattress suture, 382, 382f
- Continuous subperiosteal mattress suture, 381, 381f
- Contour augmentation, 359
- Contour grafting, 172
- COVID pandemic, 143
- Credentialing, dental photography for, 56–57
- Crestal bone, 7–8
- Crestal lift technique, 103
- Crisscross suture, 375, 375f
- Crop sensor, 59, 59f
- Cross-linked membranes, 133
- Crown lengthening, 187f, 187–188
- Crown-root fracture, 175f
- CT, 75
- C-telopeptide test, 52
- CTGs. *See* Connective tissue grafts.
- Curve of Spee, 95, 262
- Curve of Wilson, 95, 262
- Custom UCLA/milled abutments, 283, 284f
- Cytokines, 4–5
- D**
- Database marketing, 450–451
- DBBM. *See* Deproteinized bovine bone mineral.
- Delayed implant placement, 7
- Deminerized freeze-dried bone allograft, 24, 29–30, 38, 39f, 361, 389
- Dense polytetrafluoroethylene membrane, 133, 137, 439
- Dental history, 48f, 90–91
- Dental implants. *See* Implant(s).
- Dental insurance, 451
- Dental photography
- camera. *See* Camera.
  - communication uses of, 56, 56f
  - complication management uses of, 55, 55f
  - credentialing uses of, 56–57
  - extraoral, 65f, 68, 69f, 234, 234f–235f, 243f
  - flashes for, 59–60, 60f
  - full photographic series, 66, 66f–67f
  - full-face images, 67, 68f
  - HIPAA compliance for, 70
  - intraoral, 65f, 68, 69f, 235f, 235–236, 243f
  - laboratory communication uses of, 56, 57f
  - lenses for, 58–59, 59f
  - light source for, 59–60, 60f
  - marketing uses of, 55, 55f
  - media processing, storage, and optimization, 70
  - mirrors used in, 68, 69f
  - “My big 10” series, 67, 68f
  - patient communication uses of, 56, 56f
  - patient positioning for, 67–68, 69f
  - photographic presentation template, 68, 69f
  - portrait images, 67, 68f
  - profile shots, 65f
  - reasons for, 54–57
  - retractors used in, 68, 69f
  - self-critiquing uses of, 57, 57f
  - specialist referral uses of, 56, 56f
  - video gear for, 60–61, 62f
- DentaMedica, 17, 17f, 21
- Dentate patients, 265–266, 266f
- Deproteinized bovine bone mineral
- description of, 30–31, 361
  - enamel matrix derivative with, 38
- “Dermal apron” technique, 325, 325f
- Deviated nasal septum, 202, 202f, 219–220
- DFDBA. *See* Deminerized freeze-dried bone allograft.
- Diabetes mellitus
- bone metabolism affected by, 8
  - chronic, 50
  - in medical history, 50
  - type 1, 8, 50, 344
  - type 2, 8, 50, 344
- Diagnostic imaging. *See* Imaging.
- Diagnostic models, 92f, 93
- Diastema, 186f
- DICOM, 81, 126, 200
- Digital wax-up, 242
- Digital workflow, 242, 243f
- Digitally derived treatment plan, 244–245
- Direct impression, 257f, 257–258
- Disocclusion, 264
- Distraction osteogenesis, 356, 387t, 397, 439, 442
- Double interlocking continuous suture, 377, 377f
- Double surgeon’s knot, 372f
- Doxycycline, 220b
- DSL/mirrorless camera
- accessories with, 61
  - description of, 58, 58t, 59f
  - lens for, 61
  - settings for, 62
- Dual scan protocol, 83, 84f
- Dual zone therapy, 172, 173f
- Duchenne smile, 237, 237f
- Dynamic guided surgery, 104–105, 106f, 129
- Dynamic navigation, 119, 121, 128–130
- E**
- Edentulous space, 186
- Edentulous spans, 110, 356
- EMD. *See* Enamel matrix derivative.
- Enamel matrix derivative, 38
- Endocarditis, premedication for, 49
- Envelope flap, 404, 404t
- E-PRF. *See* Extended platelet-rich fibrin.
- Esthetic abutments, 282, 283f
- Esthetic risk assessment in compromised sites, 353–355, 354t
- Esthetic zone, implant placement in
- apical positioning, 193
  - bone contour augmentation, 359
  - considerations for, 171, 185, 185f
  - description of, 31f, 37
  - edentulous sites, 189
  - gingiva considerations, 187–188, 187f–188f
  - immediate implant placement, 193–194
  - implant positioning, 192–193
  - keratinized tissue, 189–190, 189f–190f
  - maxillary central incisors, 193, 197f
  - multiple missing teeth in, 195–196, 196f–197f
  - osseous morphology, 190–191, 191f–192f
  - overview of, 184–185

- restorative considerations, 185–187, 185f–187f  
 restorative materials, 194–195  
 soft tissue considerations, 187–190, 187f–190f  
 supraeruption considerations, 186f, 187
- Esthetics, 96–97, 97t
- Expanded polytetrafluoroethylene membranes, 439
- Extended platelet-rich fibrin, 153, 154f–156f
- External hex connection abutments, 275, 275f
- Extraction sockets. *See* Socket(s).
- Extraoral block grafts, 442
- Extraoral photography, 65f, 68, 69f, 234, 234f–235f, 243f
- F**
- FATTT Assessment, 353–355, 354t
- Fatty acids, 7
- FDBA. *See* Freeze-dried bone allograft.
- FESS. *See* Functional endoscopic sinus surgery.
- FGGs. *See* Free gingival grafts.
- Fibrocartilage callus formation, in fracture  
 healing process, 3, 3f
- Figure 8 suture, 374, 374f
- Figure X suture, 375, 375f
- Financing of treatment, 451–452
- Fixation screws, 415
- Fixed prostheses  
 mandibular, 110–112, 111  
 Misch classification of, 253–255, 253f–255f
- Fixed-removable implant model, 445, 446f
- Flap coaptation, 417
- Flashes, 59–60, 60f–61f
- FlashKap ring flash, 60, 61f
- Flavonoids, 19
- Focal trough, 73
- Forceps, 368, 369, 369f
- Ford technique, 376, 377f
- Foreign body reaction, 5–6, 14–15
- FP1 prosthesis, 253, 253t, 260, 269, 253f
- FP2 prosthesis, 253t, 254, 260, 269, 254f
- FP3 prosthesis, 254–255, 260, 270, 270f–271f, 254f–255f
- Fracture healing  
 L-thyroxine effects on, 51  
 process of, 3, 3f
- Free gingival grafts, 302–303, 303f, 310, 315, 320f–321f, 320–322, 423, 423f
- Freeze-dried bone allograft  
 barrier membranes on, 34, 34f  
 contraindications for, 39t  
 description of, 24, 29–30, 361, 389  
 in extraction sockets, 34  
 guided bone regeneration uses of, 36  
 indications for, 39t  
 platelet-rich fibrin and, 145  
 sinus augmentation uses of, 34, 35f
- f-stop. *See* Aperture.
- Full photographic series, 66, 66f–67f
- Full-arch implant restorations  
 classification of, 260  
 dental materials used in, 260–261  
 description of, 273  
 illustration of, 268f  
 intaglio surface of, 270–271, 271f  
 material selection for, 269–270
- multiunit abutments for, 287f  
 total tooth extraction therapy during, 333
- Full-face images, 67, 68f
- Full-thickness flap, 408, 408f
- Fully edentulous patients  
 CBCT in, 78, 78f–79f  
 implant placement in, 110–115  
 interarch space evaluations in, 93  
 mandibular fixed prosthesis in, 110–112, 111  
 mandibular overdenture in, 112, 112b, 113f  
 maxillary restorations in, 113f–114f, 113–115  
 panoramic radiography of, 74f  
 periapical radiography in, 73
- Fully guided full-arch surgery. *See also* Guided surgery.  
 digital workflow for, 242, 243f  
 digitally derived treatment plan for, 244–245  
 overview of, 241–242  
 surgical guides for, 245  
 surgical visit for, 245–250, 245f–250f
- Fully guided surgery  
 adjacent teeth in, 122  
 surgical guides for, 119, 119f, 123–124
- Functional endoscopic sinus surgery, 220
- Fungal rhinosinusitis, 205, 205f
- Furcation defects, 38–39
- G**
- GBR. *See* Guided bone regeneration.
- Gingiva  
 evaluation of, 93, 187–189, 187f–188f  
 grafting of, 316  
 keratinized, 309, 318, 318t  
 margin of, 354, 354f  
 phenotypes of, 97, 97f, 187, 193, 307, 308f, 312f, 313, 317, 318f, 354–355  
 recession of, 188f, 189, 304f–305f, 311f, 322, 354  
 thickness of, 281
- Gingivectomy, 187, 187f
- Glycosylated hemoglobin, 60
- Gold abutments, 279
- Grafts. *See* Bone graft(s); Soft tissue grafting.
- Ground dentin, 39t–40t
- Growth factors  
 autogenous bone graft release of, 27, 33  
 bone cells and, 2–3  
 from platelet-rich fibrin, 141, 141f
- GTR. *See* Guided tissue regeneration.
- Guided bone regeneration  
 allografts for, 30, 36, 133  
 anatomical considerations, 396–397  
 anesthesia for, 402–403, 403t  
 antibiotic treatment after, 419  
 autogenous bone graft harvesting for, 409–410, 409f–410f  
 barrier membranes for, 148, 361, 380, 413–416  
 biologic materials and, 424  
 biologic principles of, 389–395  
 blood supply for, 392, 393f  
 bone grafts, 361, 409–410, 409f–410f, 413, 421f  
 bony walls in, 356  
 buccal flap advancement, 410–412, 411f  
 clinical case of, 136–137, 137f  
 complications of, 423–424
- description of, 387t  
 diagnosis for, 395–398  
 esthetic contour augmentation with, 356–357  
 extraction site-specific considerations for, 420–421, 420f–421f  
 flap coaptation, 417  
 follow-up for, 418–419  
 full-thickness flap reflection, 408, 408f  
 hard tissue assessment before, 395f, 395–396  
 history of, 146, 389–392  
 horizontal ridge augmentation, 148, 149f, 398, 399f  
 illustration of, 387f  
 implant placement with, 359f–360f, 359–361, 389f  
 incisions for, 403–408, 403f–408f  
 instruments for, 401, 401f  
 intramarrow decortications, 408–409, 409f  
 lingual flap advancement, 412f, 412–413  
 local anesthesia for, 402–403, 403t  
 in mandible, 406–407, 407f  
 in maxilla, 405–406, 405f–406f  
 pain management after, 419–420  
 PASS principles of, 392t, 392–395  
 patient selection for, 395  
 platelet-rich fibrin for, 146–148, 149f, 335  
 postsurgical management of, 418–420  
 presurgical preparation for, 401–402  
 primary closure, 394–395, 417–418, 422f  
 principles of, 392t, 392–395  
 rationale for, 388–389  
 resorbable membranes for, 415–416, 416f  
 socket preservation using, 132–133  
 soft tissue assessment before, 395  
 soft tissue considerations for, 423  
 stabilization for, 394, 394f, 398, 400  
 surgical steps of, 134, 135f  
 technique for, 399–420, 401t  
 titanium-polytetrafluoroethylene for, 389, 390f–391f, 390t, 391, 400, 424, 440f, 442  
 treatment planning for, 395–398  
 vertical ridge augmentation, 397, 439–441, 440f  
 wound healing after, 423
- Guided surgery. *See also* Fully guided full-arch surgery.  
 advantages of, 121  
 disadvantages of, 121f, 121–122  
 dynamic, 104–105, 106f  
 dynamic navigation, 119, 121, 128–130, 129f  
 factors that affect, 120  
 freehand surgery versus, 119  
 illustration of, 330f  
 navigation-based, 119  
 overview of, 118–119  
 rationale for, 242  
 for single-unit implant placement, 241–242  
 static guide, 104  
 surgical guides for. *See* Surgical guides.
- Guided tissue regeneration  
 clinical case of, 136–137, 137f  
 description of, 361  
 materials for, 133  
 for socket preservation, 133f  
 surgical steps of, 134, 135f
- Gummy smile, 187

## H

“H” incision, 163, 163f  
 Hader bar, 255, 256f  
 “Halo sign”, 205, 205f  
 Healing abutments, 168, 168f, 323f, 359, 384f  
 Health care installment loan, 451–452  
 Hematoma formation, in fracture healing process, 3, 3f  
 High blood pressure. *See* Hypertension.  
 HIPAA, 70  
 Horizontal centrifugation, 142–143, 142f–143f  
 Horizontal mattress suture, 378, 378f, 418f, 438f  
 Horizontal ridge augmentation  
   allograft for, 36f  
   guided bone regeneration for, 148, 149f, 398, 399f  
 Horizontal ridge resorption, 388t  
 Hounsfield units, 81, 191  
 Hyaluronic acid, 40t  
 Hybrid abutments, 277, 280, 285, 286f  
 Hyperglycemia, 8  
 Hypertension, 49  
 Hypothyroidism, 50–51

## I

IAN. *See* Inferior alveolar nerve.  
 IGF-1. *See* Insulin-like growth factor-1.  
 Imaging  
   CBCT. *See* CBCT.  
   CT, 75  
   implant site assessments using, 72  
   modalities for, 71–72  
   panoramic radiography, 73–75, 74f  
   periapical radiography, 72–73, 73f  
   radiation dosage from, 98f  
   recommendations for, 81t  
   treatment planning uses of, 98–101, 99f  
 Immediate implant placement  
   in anterior teeth sites, 176, 177f  
   buccal plate thickness assessments, 176  
   complications associated with, 180  
   CBCT of, 104f  
   contraindications for, 181t  
   in esthetic zone, 193–194  
   extraction site management before, 172, 173f–175f  
   in extraction socket, 309f  
   history of, 171  
   in molar sites, 176–180, 177f–179f  
   objectives of, 171  
   platelet-rich fibrin with, 152  
   in premolar sites, 176  
   presurgical evaluation for, 171–176, 173f–175f  
   primary stability for, 7, 180  
   prosthetic considerations, 176  
   rationale for, 171b  
   single-tooth implant, 108, 109f  
   step-by-step approach to, 180–181  
   temporization, 181  
 Immediate loading, 267  
 Immune cells, 5–6, 9. *See also* specific cell.  
 Immune health, 14–15  
 Immune system, 14

## Implant(s)

algorithm for, 232f  
 angled, 278, 280, 356, 357f  
 in anterior teeth, 321f  
 biologic width around, 6  
 bone remodeling effects on, 6  
 contraindications for, 90–91  
 distribution of, 268–269  
 early failure of, vitamin D deficiency and, 7–8, 16, 16t, 19–21  
 forces acting on, 94  
 history of, 89–90, 170–171  
 immediate loading of, 267  
 impressions for, 256–258, 257f, 261  
 keratinized tissue around, 318, 318t  
 length of, 163  
 marketing of, 444–452  
 mini-transitional, 298, 299f  
 narrow-diameter, 298  
 number of, 268–269  
 osseointegration of. *See* Osseointegration.  
 overdentures. *See* Overdentures.  
 platelet-rich fibrin uses with, 151–152, 153f  
 positioning of, 192–193, 296–297, 356, 357f  
 primary stability of, 7, 180, 268f  
 prosthesis types, 106f, 106–107  
 screw-retained. *See* Screw-retained implants.  
 single-tooth, 96, 107–108, 108f, 241  
 site assessments for  
   CBCT for, 79f, 79–81  
   objectives, 72  
   splinting of, 108–110  
   square-shaped, 97  
   success rates for, 272  
 surface of  
   corrosion of, 8  
   decontamination of, 152  
   macrophage accumulation on, 5  
   multinucleated giant cell accumulation on, 6  
   tilted, 113, 115f, 233f, 233–234  
   width of, 163  
 Implant and three-unit partial denture model, 445, 446f  
 Implant insertion torque, 6–7  
 Implant models, 445–446, 446f  
 Implant mucosal index, 341t  
 Implant placement  
   assessment of, 87–88  
   bone evaluations for, 101–102, 360f  
   complications of, 86  
   contour augmentation with, 37  
   delayed, 7  
   in diabetes mellitus patients, 50  
   drilling procedure for, 165–167, 165f–167f  
   in esthetic zone. *See* Esthetic zone.  
   factors that affect, 87  
   flap designs for, 163–164, 164f  
   in fully edentulous patients, 110–115  
   guided bone regeneration with, 359f–360f, 359–361  
   “H” incision for, 163, 163f  
   healing abutment, 168, 168f, 323f  
   imaging after, 207  
   immediate. *See* Immediate implant placement.

incision for, 163, 163f–164f  
 in mandible, 297  
 in maxilla, 297  
 navigation-assisted, 129  
 osteotomy for, 165f, 165–166, 180–181  
 pain management after, 169  
 in partially edentulous patients, 108–110, 109f  
 positioning of implant, 192–193  
 in posterior maxilla, 102–104, 209  
 postoperative care, 168–169  
 predictable method for, 160–169  
 premedication before, 161  
 procedure for, 162f–168f, 162–169  
 robotics-assisted, 129  
 for screw-retained restoration, 192–193  
 single-stage, 168, 168f  
 soft tissue adaptation, 168, 168f  
 soft tissue augmentation before, 306–307, 307f  
 space requirements for, 93–94, 93f–94f  
 steps involved in, 162f–168f, 162–169  
 sterile technique for, 161  
 subantral approach to, 103t, 103–104  
 surgical guide for. *See* Surgical guides.  
 surgical setup for, 160–161, 161f  
 technique for, 167f, 167–168  
 two-stage, 168, 168f, 219  
 virtual, 81, 83  
 Implant stability quotient, 151  
 Implant–abutment connection, 273, 275–276, 279  
 Implant-retained overdentures, 112, 112b, 113f, 255, 255f, 292, 294, 294f  
 Implant-supported overdentures, 292–293, 295, 295f  
 Impressions, 256–258, 257f, 261  
 Incisal canal, 98, 193  
 Indirect impression, 257, 257f  
 Infection, sinus graft, 216, 226–227  
 Infective endocarditis, premedication for, 49  
 Inferior alveolar nerve, 98, 99f, 125f, 127f, 230, 406  
 Infraorbital canal, 100  
 Infraorbital nerve, 100  
 Injectable–platelet-rich fibrin, 143, 393, 394f  
 Insulin-dependent diabetes, 50  
 Insulin-like growth factor-1, 50  
 Intaglio design, 270–271, 271f  
 Interactive diagnostic imaging, 76  
 Interactive planning software, 104–105  
 Interarch space, 93–94, 93f–94f, 281  
 Interdental papillae, 320f  
 Interlocking continuous suture, 376, 377f  
 Internal hex connection abutments, 276, 276f  
 Internal sinus elevation  
   anatomy of, 209–211  
   bone grafts for, 214  
   complications of, 214–216, 221, 224–227  
   contraindications for, 212  
   infection after, 216  
   osseodensification for, 213, 213f  
   osteotome technique for, 212–213  
   radiographic evaluation of sinus before, 211  
   sinus elevation kit for, 213–214, 214f  
   sinus membrane perforation during, 214–216, 224–225, 225f  
   techniques for, 212–214, 213f–214f  
 International Team for Implantology, 37  
 Interpositional grafting, 438–439

Intrabony defects, 38–39  
 Intraoral photography, 65f, 68, 69f, 235f, 235–236, 243f  
 Intraosseous suture, 383, 383f  
 ION. *See* Infraorbital nerve.  
 ISO, 63t, 64  
 ISQ. *See* Implant stability quotient.  
 ITI. *See* International Team for Implantology.

## J

Juvenile diabetes, 50

## K

Keratinized gingiva, 318, 318t  
 Keratinized mucosa, 342  
 Keratinized mucosal width, 312  
 Keratinized tissue, 93, 189–190, 189f–190f, 302, 304f, 318  
 Kois Facial Reference Glasses, 234–235, 235f

## L

Labial drape, 95, 96f  
 Laboratory communication, dental photography for, 56, 57f  
 Lateral positioned flap, 304–305  
 Lateral sinus floor elevation, 151f  
 Lateral window approach, 199, 215, 223–224, 224f  
 Laurell-Gottlow suture, 378–379, 379f  
 Lenses, 58–59, 59f  
 Leukocyte and platelet-rich fibrin, 142  
 Life expectancy, 14f, 14–15  
 Lingual artery, 98, 99f  
 Lingual flap, 412f, 412–413, 437–438  
 Lingual nerve, 407  
 Lip line, 188  
 Local anesthesia, 402–403, 403t  
 Locator attachments, 255, 256f  
 Locking needle drivers, 368, 369f  
 Lost wax casting technique, 361  
 L-PRF. *See* Leukocyte and platelet-rich fibrin.  
 L-thyroxine, 50

## M

Macrophage(s)  
   in bone regeneration, 5–6  
   in bone remodeling, 3  
   cholesterol accumulation in, 7  
   M1, 5f, 5–6, 8  
   M2, 5f, 5–6  
   in osseointegration, 5  
   osteal, 5  
   polarization of, 5–6  
 Macrophage colony-stimulating factor, 2  
 Macrophage colony-stimulating factor receptor, 4  
 Magnesium, 19  
 Malocclusion, 186, 186f  
 Mandible  
   anatomy of, 44, 44f–45f, 98–100, 99f  
   anterior, 435  
   anteroposterior spread in, 95  
   arterial supply of, 44, 46f

bony structures of, 98, 100  
 CBCT of, 77f, 98–100, 99f  
 flexure of, 95  
 guided bone regeneration in, 406–407, 407f  
 periapical radiography of, 73f  
   posterior, 100, 434f, 434–435  
 Mandibular anterior tooth position, 262, 263f  
 Mandibular overdentures, 112, 112b, 113f, 294–295, 294f–295f  
 Manganese, 19  
 Marginal bone loss, 7, 339  
 Marketing, 55, 55f, 444–452  
 Mathieu needle holder, 368, 369f  
 Maxilla  
   anatomy of, 44, 44f–45f, 100–101, 101f, 220f, 405f  
   anterior, 101, 434f, 435  
   bone evaluations in, 101–102  
   CBCT of, 100–101, 101f  
   guided bone regeneration in, 405–406, 405f–406f  
   periapical radiography of, 73f  
   posterior, 100  
 Maxillary anterior tooth position, 261–262, 262f  
 Maxillary artery, 44, 46f, 210, 222, 225, 226f  
 Maxillary central incisors, 193, 197f  
 Maxillary overdentures, 114f, 292–293, 292f–293f  
 Maxillary ridge, 6  
 Maxillary sinus  
   anatomy of, 200–202, 201f–202f, 207, 209–211, 222, 222f–223f  
   antroliths of, 206f, 206–207  
   assessment of, 219–221, 220f–221f  
   blood supply to, 210–211, 222, 225–226  
   bony septa of, 201, 201f, 210, 210f  
   classification of, 222, 223t  
   concha bullosa of, 201–202, 202f  
   CBCT of, 200, 202  
   description of, 101, 200  
   diseases of, 202–207, 203f–207f, 220, 221f  
   embryology of, 200  
   hypoplasia of, 200–201, 201f  
   mucocoele of, 206, 206f  
   narrowness of, 222, 223f, 223t  
   nerve supply to, 211, 222  
   oroantral defect of, 205, 205f  
   pneumatization of, 210, 210f, 222, 227  
   radiographic evaluation of, 211  
   residual bone height classification for, 211–212, 221, 222t  
   retention pseudocysts of, 205, 206f  
   septata of, 201, 201f, 210, 210f  
   silent sinus syndrome of, 206, 206f  
   superior wall of, 222  
 Maxillary sinusitis, 202–205, 203f–205f, 219, 220b, 221  
 M-CSF. *See* Macrophage colony-stimulating factor.  
 M-CSFR. *See* Macrophage colony-stimulating factor receptor.  
 Media processing, storage, and optimization, 70  
 Medical considerations  
   clinical examination, 52–53  
   medical history. *See* Medical history.  
   medications, 51–52

Medical history  
   asthma, 49–50  
   chief complaint, 43, 47, 90  
   diabetes mellitus, 50  
   form for, 47, 48f  
   hypertension, 49  
   hypothyroidism, 50–51  
   importance of, 43  
   medications, 51–52, 91  
   myocardial infarction, 49  
   obtaining of, 90–91, 232  
   past, 47–48, 48f  
   premedication, 49  
 Medication(s). *See also* specific medication.  
   bone healing affected by, 51–52  
   bone metabolism affected by, 8  
   medical history-taking about, 51–52, 91  
 Medication-related osteonecrosis of the jaws, 51–52  
 Mental foramen, 98, 406  
 Mental nerve, 98  
 Mesenchymal stem cells, 24  
 Metal artifact reduction software, 207  
 Metal-ceramic prostheses, 253–254  
 Midcrestal incision, 434  
 Milled titanium substructure, 261  
 Mini-transitional implants, 298, 299f  
 Mirrors, 68, 69f  
 Misch classification, 252–253, 253t, 273  
 MNGCs. *See* Multinucleated giant cells.  
 Modified gingival index, 341t  
 Modified plaque index, 342t  
 Modified sulcular bleeding index scoring system, 341t  
 Molars, immediate implant placement approaches for, 176–180, 177f–179f  
 Monofilament sutures, 367  
 Monolithic zirconia, 107  
 MRONJ. *See* Medication-related osteonecrosis of the jaws.  
 MSCs. *See* Mesenchymal stem cells.  
 Mucocoele, 206, 206f  
 Mucositis, 203, 203f  
 Multifunctional appliance, 238f, 238–239  
 Multinucleated giant cells, 5–6, 31f  
 Multiplanar imaging/reformatting, 75–76  
 Multiple missing teeth  
   in esthetic zone, 195–196, 196f–197f  
   pontic for, 363–364  
 Multiunit abutments, 247–248, 247f–248f, 255, 255f, 277–278, 286–287, 287f, 330  
 Myocardial infarction, 49

## N

Narrow-diameter implants, 298  
 Nasal septum, deviated, 202, 202f, 219–220  
 Nasopalatine artery, 100  
 Nasopalatine canal, 405f  
 Navigation, 105, 119  
 Navigation-based guided surgery, 119  
 Needle holders, 368, 369f  
 Nonabsorbable sutures, 367  
 Noninfectious rhinosinusitis, 204  
 Nonsteroidal anti-inflammatory drugs, 402

## O

Obesity, 7

Occlusal bite, 245, 245f

Occlusal force, 94f, 94–95

Occlusal plane, 262, 263f

Occlusal scheme, 264f, 264–265

Odontogenic sinusitis, 204–205, 205f

OMC. *See* Osteomeatal complex.

Open book flap, 357, 358f–359f

Open tray technique, for impressions, 257f, 257–258

Oral examination

- arch shapes, 95, 95f
- caries, 91, 111f
- curve of Spee, 95, 262
- curve of Wilson, 95, 262
- description of, 91
- diagnostic models, 92f, 93
- esthetics, 96–97, 97t
- hard tissues, 93
- labial drape, 95, 96f
- occlusal force, 94f, 94–95
- periodontal disease, 91–93, 92f
- smile line, 96, 96f
- soft tissues, 93
- space requirements, 93–94, 93f–94f
- vertical dimension of occlusion, 94f, 95

Oroantral defect, 205, 205f

Osseodensification, 213, 213f

Osseointegration

- macrophages in, 5
- proinflammatory cytokines in, 5
- proton pump inhibitors effect on, 5
- vitamin D deficiency effects on, 8

Osteal macrophages, 5

Osteoblasts

- in bone remodeling, 2f, 2–3, 4f, 6–7
- derivation of, 2–3

Osteoclasts

- in bone remodeling, 2f, 2–4, 4f
- cytokines from, 4

Osteoconductive, 31, 133

Osteocytes, 2–4

Osteogain, 40t

Osteogenic, 25–26, 133

Osteoid, 4, 4f

Osteoinductive, 25–26, 40t, 133

Osteoinductive synthetic bone grafts, 40t

OsteoMacs. *See* Osteal macrophages.

Osteomeatal complex, 100, 219, 221–222

Osteoporosis

- antiresorptive agents for, 51
- peri-implantitis and, 344
- vitamin D and, 8

Osteotomy

- alveoloantral artery injury during, 226t
- for implant placement, 165f, 165–166, 180–181
- for internal sinus elevation, 212–213
- sinus membrane perforation during, 225

Overdentures

- abutments for, 298, 299f
- bone for, 296
- classification of, 292
- implant-retained, 112, 112b, 255, 255f, 292, 294, 294f

implant-supported, 292–293, 295, 295f

interarch space requirements for, 94, 94f

maintenance of, 300

mandibular, 112, 112b, 113f, 294–295, 294f–295f

maxillary, 114f, 292–293, 292f–293f

metal substructures in, 300, 300f

prosthetic design considerations, 298, 300

splinting of, 293

treatment planning for, 295–300, 296–300

Oxidative stress, 18

## P

Panoramic radiography, 73–75, 74f, 200, 250f

Papilla, 185, 185f

Papilla sling mattress suture, 380, 380f

Papilla sling suture, 379, 380f

Papilla-sparing incision, 164f

Paralleling technique, for periapical radiography, 72, 86

Partial extraction therapy

- benefits of, 333
- complications of, 333–336, 334f
- external shield exposure caused by, 333, 334f
- for full-arch restoration, 330f–332f, 330–333
- internal shield exposure caused by, 333, 334f, 336
- overview of, 327–328
- pontic shield technique, 328
- proximal shield technique, 328, 331–332
- root membrane technique, 328
- root submergence technique, 328, 331f, 331–332, 334f
- shield mobility caused by, 334–336, 335f
- for single-tooth restoration, 328, 329f
- socket shield technique, 328, 329f, 330, 330f, 333, 334f

Partially edentulous patients

- illustration of, 266f
- implants in, 108–110, 109f
- periodontal examination in, 92

Partially guided surgery, surgical guides for, 124–125

Passive fit, 274, 277

Past medical history, 47–48, 48f

Patient

- age of, 90
- communication with, dental photography for, 56, 56f

Pay-per-click, 449–450

PDL. *See* Periodontal ligament.

Pedicle flap, 304–305

Pedicle graft, 323, 324f

PEEK, 279

Periapical radiography, 72–73, 73f

Peri-implantitis

- aging and, 344–345
- bone defect morphology, 346f–350f, 346–350
- confounders of, 342–343
- definition of, 338–339
- description of, 91, 152, 163, 163f
- diagnosis of, 340, 341f
- illustration of, 312f, 339f, 341f
- keratinized tissue, 312, 313f
- monitoring of, 341–342
- onset of, 342

predisposing factors for, 343, 343f

prevalence of, 339, 340t

progression of, 342

soft tissue augmentation for, 312–313, 313f–314f

systemic drivers of, 343–345

treatment of, 345–350, 346t

Periodontal disease, 52, 91–93, 92f, 188–189, 189f, 266, 311f

Periodontal examination, 92f, 92–93

Periodontal ligament, 94, 101

Periodontal phenotype, 319

Periodontal probing, 92f

Periodontal regeneration, 38–39

Periodontitis, 343

Periosteal releasing incisions, 410, 411f, 437f

Periosteal sutures, 399f, 436f

PES. *See* Pink esthetic score.

PE'T. *See* Partial extraction therapy.

Photography. *See* Dental photography.

Piezosurgery, 27, 28f

Pilot drill guides, 119, 119f, 123, 123f

Pink esthetic score, 96–97, 97t

Platelet concentrates, 141–142

Platelet-rich fibrin

- bone grafts and, 145, 149, 393
- clinical uses of, 144–152, 147f, 149f, 151f
- concentrated-, 143
- description of, 34, 38–39, 140–141
- development of, 141–142
- extended, 153, 154f–156f
- extraction site management uses of, 144–146
- growth factors released from, 141, 141f
- guided bone regeneration uses of, 146–148, 149f, 335
- horizontal centrifugation production of, 142–143, 142f–143f
- implant dentistry uses of, 151–152, 153f
- injectable-, 143, 393, 394f
- injectable biologic filler material use of, 153, 156g
- natural wound healing versus, 144–145
- recession coverage uses of, 153, 155f
- sinus grafting uses of, 149–151, 151f
- sinus membrane perforation treated with, 215
- socket preservation and grafting uses of, 144–146, 147f
- soft tissue augmentation with, 152, 153f, 336

Platelet-rich plasma, 141

Pocket probing depth, 339, 341, 341f, 345

Podosomes, 2

Poliglecaprone sutures, 371, 371t

Polyglycolic acid sutures, 371, 371t

Polypropylene sutures, 371, 371t

Polytetrafluoroethylene membranes, 389, 413

Polytetrafluoroethylene sutures, 371t, 371–372

Polyvinyl siloxane, 257, 257f

Pontic, for multiple missing teeth, 363–364

Pontic shield technique, 328

Porcelain-fused-to-metal restorations, 194, 261, 265, 269, 282f, 359f

Portrait images, 67, 68f

Posterior maxilla

- anatomy of, 100
- augmentation of. *See* Internal sinus elevation.
- description of, 435



- edentulism of, 200  
 implant placement in, 102–104, 209  
 Posterior superior alveolar artery, 100, 101f, 210–211  
 PPC. *See* Pay-per-click.  
 PPD. *See* Pocket probing depth.  
 Premedication, 49  
 Premolars, immediate implant placement  
   approaches for, 176, 177f  
 PRF. *See* Platelet-rich fibrin.  
 Primary hypothyroidism, 50  
 Primary septa, of maxillary sinus, 210  
 Proinflammatory cytokines, 5  
 Prosthesis  
   fixed, 253–255, 253f–255f  
   Misch classification of, 252–253, 253t  
   options for, 252–256  
   overdentures and, 298, 300  
   removable, 255–256, 255f–256f  
   terminology associated with, 260  
   types of, 106f, 106–107  
 Prosthetic heart valves, premedication for, 49  
 Prosthetic joint infections, 49  
 Prosthodontics  
   mandibular anterior tooth position, 262, 263f  
   maxillary anterior tooth position, 261–262, 262f  
   occlusal plane, 262, 263f  
   occlusal scheme, 264f, 264–265  
   vertical dimension of occlusion, 263  
 Proton pump inhibitors, 51  
 Provisionalization, 267–268  
 Proximal shield technique, 328, 331–332  
 PRP. *See* Platelet-rich plasma.  
 PSAA. *See* Posterior superior alveolar artery.  
 Pseudocysts, 205, 206f  
 Pterygoid implants, 115, 115f  
 PTFE membranes, 34, 34f  
 Pyridoxine, 19
- R**
- Radiation dosage, 98f  
 Radiographic stent with opaque markers, 74, 74f  
 Radiography  
   panoramic, 73–75, 74f, 200, 250f  
   periapical, 72–73, 73f  
 Radiologic guide, 83–85, 84f  
 RANKL, 2, 6  
 RANKL inhibitors, 51  
 RAP. *See* Regional acceleratory phenomenon.  
 Reactive oxygen species, 18  
 Receptor activator of nuclear factor kappa-B  
   ligand. *See* RANKL.  
 Recombinant human BMP-2, 26f, 32, 37f  
 Recombinant human BMP-9, 40t  
 Regional acceleratory phenomenon, 133–134, 409, 439  
 Removable prosthesis, 255–256, 255f–256f  
 Rescue procedures, soft tissue augmentation as, 310, 312  
 Residual bone height, 211–212, 221, 222t  
 Resorbable membranes, 415–416, 416f  
 Restorative space, 260, 296  
 Retention pseudocysts, 205, 206f  
 Retirement savings plan, 451
- Retractors, 68, 69f  
 Rhinosinusitis, 203–204, 203f–204f, 219, 220b  
 Riboflavin, 19  
 Ridge resorption, 306  
 Ridge splitting, 387t  
 Rigid guides, 120–121  
 Ring flashes, 59–60, 60f–61f  
 Robotics, 129, 129f  
 Root form implants, 90, 137, 137f  
 Root membrane technique, 328  
 Root submergence technique, 328, 331f, 331–332, 334f  
 ROS. *See* Reactive oxygen species.  
 RP4 prosthesis, 255–256, 255f–256f  
 RP5 prosthesis, 256, 256f
- S**
- Salvin Lindemann side-cutting bur, 166, 166f  
 Schneiderian membrane. *See* Sinus membrane.  
 Scissors, 370, 370f  
 Sclerostin, 7  
 Screw retention, 260  
 Screw-retained implants  
   abutments for, 277, 281, 285, 285f  
   cement-retained restorations versus, 280  
   description of, 108, 108f  
   multiunit abutments for, 286, 287f  
   positioning of, 192–193  
   titanium-base abutments for, 286  
 Screw-retained provisional restoration, 363f  
 SCTGs. *See* Subepithelial connective tissue grafts.  
 Search engine optimization, 448–449  
 Secondary septa, of maxillary sinus, 210  
 Segmentation, 85, 128f  
 Seibert classification, 396  
 Selenium, 19  
 SEO. *See* Search engine optimization.  
 Septa, of maxillary sinus, 201, 201f, 210, 210f  
 Serotonin reuptake inhibitors, 51  
 Shutter speed, 63, 63t  
 Silent sinus syndrome, 206, 206f  
 Simple continuous suture, 376, 376f  
 Simple interrupted suture, 373, 374f, 394f  
 Single-tooth implants, 96, 107–108, 108f, 241  
 Sinus augmentation  
   anatomy of, 200–207, 222, 222f–223f  
   bleeding caused by, 225–226  
   bone grafts for, 34–35, 35f  
   imaging after, 207  
   indications for, 221  
   infection after, 226–227  
   lateral window approach, 199, 223–224, 224f  
   overview of, 218–219  
   platelet-rich fibrin for, 149–151, 151f  
   posterior maxilla. *See* Internal sinus  
     elevation.  
   postoperative infection after, 221, 221f  
   sinus assessments before, 219–221, 220f–221f  
   xenografts for, 35, 35f  
 Sinus Consensus Conference, 211–212  
 Sinus elevation kit, 213–214, 214f  
 Sinus elevation surgery. *See* Internal sinus  
   elevation.  
 Sinus membrane  
   description of, 211  
   perforation of, 214–216, 224–225, 225f–226f
- Sinusitis, maxillary, 202–205, 203f–205f, 219, 220b, 221  
 Smartphone camera, 57–58, 58f  
 Smile line, 96, 96f, 187, 187f, 295, 297f  
 Smoking, 344  
 Socket(s)  
   anatomy of, 134  
   bone grafts in, 34, 34f  
   classification of, 132, 132f, 178f  
   cleaning of, 172  
   molar, 178, 178f  
   remodeling of, 131  
   resorption of, 101  
   staged augmentation of, 357, 358f  
   suture closure of, 135–136, 136f  
   types of, 107  
 Socket preservation and grafting  
   allografts, 133  
   autografts, 132  
   buccal flap in, 138–139  
   clinical case of, 136–137, 137f  
   guided bone regeneration for, 132–133  
   guided tissue regeneration for, 133  
   instrumentation for, 138, 138f  
   materials for, 133  
   platelet-rich fibrin uses in, 144–146, 147f  
   prevalence of, 132  
   rationale for, 132  
   soft tissue augmentation for, 306  
   surgical procedure for, 134–136  
   wound healing in, 133–134  
   xenografts used in, 133  
 Socket shield technique, 328, 329f, 330, 330f, 333, 334f  
 Soft tissue. *See also* Gingiva.  
   biotype of, 296  
   labial, 357f  
 Soft tissue graft(s)  
   acellular dermal connective tissue grafts, 304, 304f, 319, 324–325, 325f  
   allografts, 305, 319, 324–325  
   connective tissue grafts, 302–305, 304f–305f  
   free gingival grafts, 302–303, 303f, 310, 315, 320f–321f, 320–322  
   lateral positioned flap, 304–305  
   overview of, 302–303  
   pedicle flap, 304–305  
   purposes of, 316  
   subepithelial connective tissue grafts, 302–304, 304f, 306–307, 308f, 310, 311f, 322–323, 323f, 325, 336  
   types of, 319  
   xenografts, 324–325  
 Soft tissue grafting  
   before bone augmentation, 306–307  
   before implant placement, 306–307, 307f  
   keratinized gingiva for, 318, 318t  
   for peri-implantitis, 312–313, 313f–314f  
   reasons for, 319  
   in rescue procedures, 310, 312  
   at stage-two implant surgery, 309–310  
 Soft tissue-supported guides, 105, 120  
 Specialist referrals, 56, 56f  
 Splinted overdentures, 293

- Splinted restorations, 278
- Splinting, 108–110
- SSRIs. *See* Serotonin reuptake inhibitors.
- Stabilizing sutures, 436, 436f
- Stage-two implant surgery, 309–310
- Statins, 51
- StellaLife Recovery kit, 9, 9f
- Stem cells, 387
- Stereolithography file, 82, 125f
- “Sticky bone,” 143, 143f, 148, 393
- STL file. *See* Stereolithography file.
- Straight implants, 278
- Subantral augmentation, 103, 103t
- Subepithelial connective tissue grafts, 302–304, 304f, 306–307, 308f, 310, 311f, 322–323, 323f, 325, 336
- Subperiosteal implant, 89
- Subperiosteal mattress suture, 380–381, 381f
- Superstructure, 274
- Suppuration grading index, 341, 342t
- Supraeruption, 186f, 187
- Surface rendering, 75
- Surgeon’s knot, 372f, 372–373
- Surgical guides
  - bone-borne, 126–127, 127f–128f
  - CBCt used to create, 85, 86f
  - creation of, 125f–126f, 125–127
  - fabrication of, 162–163, 163f
  - for fully guided surgery, 119, 119f, 123–124, 245
  - metal sleeves in, 120
  - for partially guided surgery, 124–125
  - pilot drill guides, 119, 119f, 123, 123f
  - rigid, 120–121
  - soft tissue-supported, 105, 120
  - tooth-borne, 125f–126f, 125–126
  - tooth-supported, 104–105
  - types of, 119, 119f
- Surgical veneer grafting, 172, 174f
- Surgical workup, 47
- Suture(s)
  - absorbable, 367
  - braided, 367
  - characteristics of, 366–367
  - chromic gut, 371, 371t
  - gauge of, 367, 367t
  - monofilament, 367
  - nonabsorbable, 367
  - poliglecaprone, 371, 371t
  - polyglycolic acid, 371, 371t
  - polypropylene, 371, 371t
  - polytetrafluoroethylene, 371t, 371–372
  - removal of, 419
  - silk, 367f, 371, 371t
  - thickness of, 367, 367t
  - types of, 370–372, 371t
  - Vicryl, 371, 371t
- Suture grooves, 384, 384f
- Suture knots, 372f, 372–373
- Suture needles, 368, 368f
- Suturing
  - bisecting wound technique, 374, 375f
  - continuous horizontal mattress suture, 382, 382f
  - continuous subperiosteal mattress suture, 381, 381f
  - crisscross suture, 375, 375f
  - double interlocking continuous suture, 377, 377f
  - figure 8 suture, 374, 374f
  - figure X suture, 375, 375f
  - horizontal mattress suture, 378, 378f, 418f
  - interlocking continuous, 376, 377f
  - intraosseous suture, 383, 383f
  - knots, 372f, 372–373
  - Laurell-Gottlow suture, 378–379, 379f
  - needle holders for, 368, 369f
  - papilla sling mattress suture, 380, 380f
  - papilla sling suture, 379, 380f
  - scissors for, 370, 370f
  - simple continuous, 376, 376f
  - simple interrupted suture, 373, 374f, 394f
  - subperiosteal mattress suture, 380–381, 381f
  - summary of, 384–385
  - techniques for, 373–384, 374f–384f
  - Texas two-step suture, 382, 382f
  - tieback sutures, 383–384, 384f
  - tissue forceps for, 368, 369, 369f
  - vertical mattress suture, 379, 379f
  - W periosteal suture, 382, 383f
- Swing-out bucket centrifugation, 142
- ## T
- Tartrate-resistant acid phosphatase, 2
- Temporary cylinders, on multiunit abutments, 247, 247f, 330f
- Temporization, 181, 185
- Tentpole technique, 387t
- Tetranite bone adhesive, 40t
- Texas two-step suture, 382, 382f
- Thiamin, 19
- Thick gingival phenotype, 317, 318f
- Thin gingival phenotype, 308f, 317, 318f, 354
- 3D printed bone grafts, 40t
- Three-united fixed partial denture, 196f
- Thyroid hormone, 50
- Tieback sutures, 383–384, 384f
- Tilted implants, 113, 115f, 233f, 233–234
- Tissue engineering, 25
- Tissue forceps, 368, 369, 369f
- Titanium implant
  - history of, 89
  - hypersensitivity to, 8
  - surfaces of, 5
- Titanium mesh, 413, 414f, 439
- Titanium-base abutments, 194, 279, 285, 286f
- Titanium-polytetrafluoroethylene, 389, 390f–391f, 390t, 400, 413, 424, 440f
- Tooth extraction site management
  - bacterial infections, 172
  - for immediate implant placement, 172, 173f–175f
  - platelet-rich fibrin in, 144–146
  - strategic staging, 361
- Tooth loss, 170, 388
- Tooth-supported guides, 104, 104f
- Transgingival probing, 317
- Transition line/zone, 260
- TRAP. *See* Tartrate-resistant acid phosphatase.
- Trapezoid flap, 404, 404t
- Treatment financing, 451–452
- Treatment planning
  - bone evaluations, 101–102
  - description of, 63
  - digitally derived plan, 244–245
  - in esthetic zone, 185f
  - imaging uses for, 98–101, 99f
  - interactive software for, 104–105
  - materials, 269–270
  - medical history for. *See* Medical history.
  - number and distribution of implants needed, 268–269
  - oral examination in. *See* Oral examination.
  - for overdentures, 295–300, 296–300
  - photographs used in, 56
  - presenting situation, 265–267, 266f–267f
  - provisionalization, 267–268
  - single-tooth implants, 107–108, 108f
  - verbal skills for treatment plan presentation, 446–448
- Triangular flap, 404, 404t, 406f
- Trigeminal nerve, 44, 45f
- Twin flashes, 60, 61f
- Two-stage implant technique, 168, 168f, 219
- ## U
- UCLA abutments, 283, 284f
- Universal precautions, 160
- ## V
- VDO. *See* Vertical dimension of occlusion.
- Vertical dimension of occlusion, 94f, 95, 126, 236f, 236–237, 239, 263
- Vertical mattress suture, 379, 379f
- Vertical ridge augmentation, 397, 432–442
- Vertical root fracture, 179f
- Vestibular incision subperiosteal tunnel access, 172
- Vicryl sutures, 371, 371t
- Video gear, 60–61, 62f
- Video testimonials, 450
- VISTA. *See* Vestibular incision subperiosteal tunnel access.
- Visual records, 54–57
- Vitamin A, 19
- Vitamin B1, 19
- Vitamin B2, 19
- Vitamin B6, 19
- Vitamin C, 18–19
- Vitamin D
  - bone metabolism affected by, 7–8
  - description of, 7–8
  - food sources of, 15
  - functions of, 14
  - levels of
    - classification of, 15, 15t
    - testing of, 16–17, 17f, 21
  - osteoporosis and, 8
  - supplementation of, 15, 17, 17f, 21
  - wound healing functions of, 18
- Vitamin D deficiency
  - bone-to-implant contact affected by, 15–16
  - dental-related complications associated with, 15–16
  - diseases associated with, 14
  - early implant failure and, 7–8, 16, 16t, 19–21

levels of, 15, 15t  
 osseointegration effects of, 8, 15–16  
 prevalence of, 18b, 21

**W**

W periosteal suture, 382, 383f  
 Wax-up, 242  
 Websites, 448–450, 449f  
 WES. *See* White esthetic score.  
 White esthetic score, 96, 97t  
 Wnt signaling pathway, 7  
 Workup, 47  
 Wound healing  
   antioxidants in, 17–18  
   B vitamins in, 19  
   blood clot in, 134  
   carotenoids in, 19  
   flavonoids in, 19  
   magnesium in, 19

manganese in, 19  
 platelet-rich fibrin versus, 144–145  
 selenium in, 19  
 in socket preservation and grafting, 133–134  
 vitamin C in, 18  
 vitamin D in, 18  
 zinc in, 19

**X**

Xenografts  
   advantages of, 30, 393t  
   allografts versus, 30  
   autografts and, 28, 36–37  
   bone regeneration uses of, 2, 133  
   classification of, 24f  
   contraindications for, 39t  
   deproteinized bovine bone mineral, 30–31  
   future research in, 39  
   indications for, 39t

for internal sinus elevation, 214  
 properties of, 25t  
 proportional use of, 34, 34f  
 regenerative properties of, 33–34, 34t  
 sinus augmentation uses of, 35, 35f  
 socket grafting uses of, 133  
 soft tissue, 307, 308f, 324–325

X-NAV, 129, 129f

**Y**

Y-point, 166

**Z**

Zinc, 19  
 Zirconia abutments, 194, 274, 279–280  
 Zirconia prostheses, 253f, 253–254  
 Zygomatic implants, 113–115, 115f, 156f